At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 213 enrolled
Drug / intervention
AZD7624 1.0 mg +1 moredrug
Likely dose
AZD7624 1.0 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A 12-week Phase IIa, Double-blind, Placebo-controlled, Randomized Study to Investigate the Efficacy and Safety of AZD7624 in COPD Patients With a History of Frequent Acute Exacerbations While on Maintenance Therapy
In Brief
A Phase 2 clinical trial evaluating AZD7624 1.0 mg and Placebo for Chronic Obstructive Pulmonary Disease COPD. Completed, enrolled 213 participants across 41 sites in 6 countries.
Detailed Summary
The purpose of this study is to determine whether AZD7624 can reduce acute Chronic Obstructive Pulmonary Disease (COPD) exacerbations in patients on COPD maintenance therapy with a history of frequent acute exacerbations.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesArgentina, Chile, Netherlands, Peru, South Africa, United States
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 2014
Enrollment StartOct 2014
Primary CompletionApr 2016
TodayJul 2026
First PostedSep 12, 2014
Enrollment StartOct 28, 2014
Primary CompletionApr 4, 2016
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 11.8 years ago
Interventions
AZD7624 1.0 mgdrug
Inhaled AZD7624 solution, 11 mg/mL
Placebodrug
Inhaled placebo solution